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Abstract
A proportion of breast carcinomas develop as a result of a genetic predispostion to the
disease. Prior to cloning of the BRCA1 and BRCA2 genes a limited number of studies were
carried out to identify specific histopathological characteristics of hereditary breast cancer.
These studies are the subject of this review. The main finding was the association of the
(atypical) medullary type of breast cancer with a family history; the most important caveat
being that medullary breast cancer is found more frequently in young patients. In view of
the frequent bilateral occurrence of lobular cancer, this histologic type is also likely to be
associated with a predisposing genetic defect. Future investigations will have to test this
hypothesis. In addition to mutations in the BRCA1 and BRCA2 genes, there are as yet
unidentified genetic defects predisposing to breast cancer development, and histopathology
may well help in identifying these genes in the future.
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Introduction
Anecdotal evidence from individual families in which
breast cancer occurs very frequently and large epidemio-
logical studies have shown that some women have a famil-
ial predisposition to breast cancer. The anecdotal
evidence includes the pedigree of Broca’s family [1]. He
was a famous French surgeon (1824–1880), and in his
family tree (which comprised over five generations) 10 out
of 24 women died of breast cancer. Systematic epidemio-
logical studies performed in the second half of the 20th
century have shown that, in women with a family history
of breast cancer, the risk of breast cancer is increased two-
to threefold (‘familial breast cancer’). Such studies have
also shown that there are families in which breast cancer
risk is inherited in an autosomal-dominant fashion
(‘hereditary breast cancer’). In recent years, it has been
shown that germline mutations in the BRCA1 and BRCA2
genes account for a large proportion of cases of hereditary
breast cancer.
Histopathological findings and careful autopsy examina-
tion have played a major role in the recognition of many
familial cancer syndromes [2], including multiple
endocrine neoplasia type II and Beckwith–Wiedemann
syndrome. The creation of tissue archives that include a
coded index of patient details, tissue and diagnosis at a
time when the possibilities for its use were remote has
placed pathologists in a unique position to play a central
role in familial breast cancer research. The knowledge of
the histopathological features will also help in understand-
ing the genetic defects that underlie the various forms of
familial predisposition. Histopathological diagnosis and
tissue archives may therefore be of fundamental impor-
tance in our understanding of familial breast cancer, and
hospitals would be wise to look after this unique resource.
This review describes histopathological studies with regard
to specific histological features of breast carcinoma in
patients who have developed this disease as part of what wasBreast Cancer Research    Vol 1 No 1 van de Vijver
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described as ‘familial breast cancer’ or ‘hereditary breast
cancer’ before the identification of the BRCA1 and BRCA2
genes. The histological features of breast carcinomas arising
in patients with germline mutations in the BRCA1 or BRCA2
genes are discussed in this issue by Lakhani.
In addition to mutations in the BRCA1 and BRCA2 genes,
there are as yet unidentified genetic defects that predis-
pose to breast cancer development, and histopathology
may well help in identifying these genes in the future.
Histopathology of breast cancer in patients
with a family history of breast cancer
Breast cancer is a very heterogeneous disease that is char-
acterized by a number of histopathological subtypes. The
major histological types of breast cancer and an estimate of
their relative contribution are shown in Table 1. As can be
seen from this table, the vast majority of breast carcinomas
fall into the category ‘ductal, not otherwise specified’; of
note is that the tumours in this category still show hetero-
geneous morphology. Ductal carcinomas not otherwise
specified can be divided into subgroups with different
grades of malignancy on the basis of degrees of differenti-
ation, pleomorphism and mitotic activity.
Breast cancer is a common disease, occurring in approxi-
mately one in 12 European or North American women. In
part, clustering of breast cancer in a family is a result of
chance, because breast cancer is so frequent; in some fam-
ilies, the clustering is the result of shared environmental
risk factors; and in a proportion of families an underlying
genetic defect will be the culprit. Before the identification
of the BRCA1 and BRCA2 genes, it was impossible to dis-
criminate between these possibilities. This still applies to
all other as yet unidentified genetic defects that predis-
pose to breast cancer.
There have been a limited number of studies that have
described histopathological features in association with
the presence of a family history. In a comprehensive
review of the literature through the early 1980s, Mulcahy
and Platt [3] concluded that most studies have been
extremely small or did not represent population-based
samples. Since then, there have been two large popula-
tion-based studies [4••,5••]. The main features and conclu-
sions of these two studies are summarized in Table 2.
In addition to family history, a number of other patient
characteristics have been found to be associated with his-
tological type. For example, patients with medullary
breast cancer have been reported to be younger than those
with other histological types, and medullary carcinomas
have been reported to be more frequent in blacks than in
whites [5••]. A comprehensive review of the histopathol-
ogy of familial breast cancer and of breast cancer in young
women was presented by Marcus et al [6•].
Historically, familial breast cancer has been found to be
associated with medullary carcinoma, tubular carcinoma
and lobular carcinoma. These are considered briefly below.
Medullary carcinoma
In patients who had a mother with breast cancer, Rosen et
al [4••] found medullary cancer in 16% and atypical
medullary cancer in 18% of women. Of note is that these
authors did not find an increased frequency of medullary
cancer in patients who had a sister with breast cancer, an
observation that was also made by Anderson in 1994 [6].
Claus et al [5••] found an increased frequency of medullary
cancer in young women, but no association with family
history. An important caveat with respect to the diagnosis
of medullary carcinoma is that there is considerable inter-
observer variability in making this diagnosis. It is clear,
however, that tumours with features that are consistent
with medullary carcinoma are more frequent in patients
with a family history and in younger patients. Probably the
most important property of these tumours is a high prolif-
erative activity, resulting in a tumour with pushing
margins and high mitotic count.
Tubular carcinoma
Lagios et al [7] identified 17 tubular cancers in mastectomy
specimens from a cohort of 211 breast cancer patients. A
family history that was positive for mammary carcinoma in a
first-order relative was recorded for six out of 15 patients
analyzed (40% versus 16% in the patients with other histo-
logical types of breast cancer).
Lobular carcinoma in situ and invasive lobular carcinoma
Among the histopathological types of breast cancer,
lobular cancer stands out as a candidate for a tumour
caused by a genetically inherited predisposition. The
main reason for this is the high frequency of bilateral inva-
sive and in situ lobular breast cancer. Claus et al [5••] found
Table 1
Histological classification of invasive breast cancer, including
the estimated proportion of all breast carcinomas for each
histologic type
Histologic type Estimated frequency (%)
Ductal carcinoma, not otherwise specified 70
Lobular carcinoma 10
Tubular carcinoma 5
Mucinous carcinoma 5
Medullary carcinoma 3
Atypical medullary carcinoma 3
Other (metaplastic, papillary, adenoid cystic, etc) 429
http://breast-cancer-research.com/vol1no1/27oct99/review/1
that patients with lobular carcinoma in situ were more
likely than patients with other histopathological types of
breast cancer to have a mother and/or sister who had
breast cancer. In their series, lobular carcinoma in situ was
bilateral in 27% of cases [5••]. Rosen et al [4••] found that
17% of patients who had one or more sisters with breast
cancer were of lobular histologic type.
It is likely that lobular cancer develops as part of an inher-
ited predisposition, and that this is due to low penetrance
gene(s). Mutations in the E-cadherin gene can be identi-
fied in the majority of lobular carcinomas. These muta-
tions are all somatic mutations, however, and germline
mutations have not been identified in patients with
lobular cancer [8,9].
Can preneoplastic histopathological breast
alterations be identified in familial breast
cancer?
A number of histologic alterations of the breast have been
identified, which are associated with an increased risk of
developing breast cancer. These histologic alterations
include epithelial hyperplasia, atypical ductal hyperplasia
[10], fibroadenoma with ‘complex features’ [11], scar
lesions [12] and cysts [13]. These conditions are all associ-
ated with an increased risk of developing breast cancer in
both breasts (and not only in the breast from which the
tissue showing these histological alterations has been
excised). To date, there is no evidence that they are direct
precursors of breast carcinoma, and they should be viewed
as markers of increased risk. The mechanism that under-
lies the association of these lesions with increased risk of
breast cancer development is currently unknown. If
epithelial hyperplasia, atypical ductal hyperplasia,
fibroadenoma with ‘complex features’ or scar lesions are
present, the risk of developing breast cancer is roughly
doubled if there is also a family history of breast cancer.
Fine needle aspiration from all four quadrants of both
breasts has been performed in women without breast
abnormalities [14], and it was noted that an increased fre-
quency of ‘atypical ductal hyperplasia’ was found in
women with a family history of breast cancer compared
with women without a family history. As has also been
pointed out in other reviews in this issue, atypical ductal
hyperplasia is a histological diagnosis that cannot been
made on the basis of cytological examination. Therefore,
these findings cannot be taken as evidence that preneo-
plastic conditions can be diagnosed in women with a
familial predisposition to develop breast cancer.
Ductal and lobular carcinoma in situ are the only known
direct precursor lesions to breast cancer, and ductal carci-
noma in situ has not been reported in association with
breast cancer family history. In a series of 605 bilateral
prophylactic mastectomies performed because of a family
history of breast cancer [15], not one case of carcinoma in
situ was found.
It must be realized that it is difficult to find microscopic
precursor lesions to invasive breast cancer if these lesions
cannot be detected using mammography or magnetic res-
onance imaging. The pathological examination of a pro-
phylactic mastectomy specimen will include taking
several sections from macrosopically normal parts of the
breast, usually resulting in examination of less than 1% of
all breast tissue. Because it is to be expected that cancer
will start in one (microscopic) area of the breast (which is
also the case when there is a germline gene mutation pre-
disposing to breast cancer), the risk of finding such a
minute lesion is small. Germline mutations in BRCA1,
BRCA2 and other genes could theoretically also lead to
multiple or even diffuse histological alterations (for
instance multiple foci of proliferation of dysplastic
epithelium, analogous to multiple polyps in familial ade-
nomatosis coli). Such diffuse alterations in the breast
have not been identified to date, however, and it is very
unlikely that they are present.
Breast cancer histopathology in other cancer
syndromes
Cancer syndromes that are also associated with an
increased risk of developing breast cancer include Cow-
den’s disease, the Li-Fraumeni cancer syndrome and
ataxia–telangiectasia. No studies of the histopathological
features of breast carcinomas that occur in patients with
these syndromes have been published.
Table 2
Selected studies of the relationship between histopathology of breast carcinoma and family history
Author n Study design Main conclusions
Rosen et al [4••] 1024 Breast cancer histology associated with Medullary cancer is associated with maternal breast 
family history (consecutive series of patients cancer; lobular cancer is associated with breast cancer 
treated at Memorial Hospital, New York) in a sister
Claus et al [5••] 4071 Breast cancer histology associated with Medullary cancer is associated with young age; lobular 
epidemiological factors: part of the Cancer carcinoma in situ is associated with family history
and Steroid Hormone studyConclusion
Before the cloning of the BRCA1 and BRCA2 genes, a
number of studies reported an association of histopatho-
logical type with a family history, but these studies have
been difficult to interpret due to the small number of
samples and differing criteria for ‘positive family history’
and pathological typing. Hence, there are only limited
data on specific histologic patterns in breast carcinomas
that are associated with hereditary and familial breast
cancer. The main finding was the association of the
medullary type of breast cancer with a family history; the
most important caveat being that medullary breast cancer
is found more frequently in young patients. As is seen
elsewhere in this review series, the association of family
history with medullary breast cancer is now confirmed by
studies based on knowledge of BRCA1 and BRCA2
mutation status.
In view of the frequent bilateral occurrence of lobular
cancer, this histological type is also likely to be associated
with a predisposing genetic defect. Future investigations
will have to test this hypothesis.
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